Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids

Interaction between Her2 and Beclin-1 Proteins Underlies a New Mechanism of Reciprocal Regulation

(2013) Jie Han et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib

(2013) Xingmei Zhu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Autophagy: shaping the tumor microenvironment and therapeutic response

(2013) Hannelore Maes et al.   TRENDS IN MOLECULAR MEDICINE

The tumor microenvironment is a dominant force in multidrug resistance

(2012) Ana Luísa Correia et al.   DRUG RESISTANCE UPDATES

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

(2011) R. Ghosh et al.   CANCER RESEARCH

Chromosome band 17q21 in breast cancer: Significant association between beclin 1 loss and HER2/NEU amplification

(2010) Tiziana Negri et al.   GENES CHROMOSOMES & CANCER

Autophagy Induction by Capsaicin in Malignant Human Breast Cells Is Modulated by p38 and Extracellular Signal-Regulated Mitogen-Activated Protein Kinases and Retards Cell Death by Suppressing Endoplasmic Reticulum Stress-Mediated Apoptosis

(2010) C.-H. Choi et al.   MOLECULAR PHARMACOLOGY

Paradoxial changes in the expression of estrogen receptor alpha in breast cancer multicellular spheroids

(2010) Laura Muñoz et al.   TISSUE & CELL

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

(2009) Britta Weigelt et al.   BREAST CANCER RESEARCH AND TREATMENT

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab

(2009) Alejandro Vazquez-Martin et al.   PLoS One

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab

(2008) M Pickl et al.   ONCOGENE